Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)
- February 2018 •
- 67 pages •
- Report ID: 5339941
Cells, similar to the line of uterus known as endometrium start growing on the exteriors of uterus like fallopian tube, ovaries, and other internal parts. These tissues continue to act as it does and starts to thicken and breaks down and bleeds with each menstrual cycle and gets trapped, causing painful periods and severe pelvic pain.
The primary symptoms of endometriosis include fatigue, diarrhea, constipation, bloating and severe pain. Endometriosis has multiple treatment options but GnRH agonists have also shown high responder rates and thus believed to be the best in class therapeutics to treat endometriosis because three major drugs are in their final phase of successful clinical trials. These drugs are anticipated to change the complete market scenario with their launch.
The global endometriosis market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, rise in female population, and increasing healthcare expenditure. However, the market growth is hindered by high R&D expenditures and expensive drug costs.
The report “Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)” analyzes the development of this market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: AbbVie, Myovant Sciences, ObsEva SA, and Neurocrine Biosciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global endometriosis market along with the study of the regional markets.